Songhong Zhou – Trademark Portfolio

Entity Type: 01

Songhong Zhou holds 22 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 20 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 21 trademarks are registered. Notable registered marks include ANGUISHIL, AVEGRASES, CEOTRAVEL, EIGRAMSET, and ERNITERTY. The owner is based in Nanan.

No.270, Top Village

Meilin Zhuang Ding Village

Nanan 362300 , CN

22 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Songhong Zhou's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (20 filings)

Surgical, medical, dental and veterinary apparatus and instruments

9
Computers & Electronics (2 filings)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does Songhong Zhou have?

Songhong Zhou has 22 U.S. trademarks filed with the USPTO. Of these, 21 registered, 1 abandoned.

What trademark classes does Songhong Zhou file in?

Songhong Zhou files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Songhong Zhou's most well-known trademarks?

Songhong Zhou's registered trademark portfolio includes well-known marks such as ANGUISHIL, AVEGRASES, CEOTRAVEL, EIGRAMSET, and ERNITERTY. These are among 21 currently registered trademarks in the portfolio.

What is Songhong Zhou's trademark registration success rate?

Songhong Zhou has a 95% trademark registration rate, with 21 out of 22 resolved applications resulting in successful registration. Currently, 0 applications are pending review.